Keywords
surgical treatment of metastases
systemic inflammatory response index
How to Cite
Abstract
In press
Inflammatory reactions to surgical interventions pose a risk of postoperative complications and affect the further course of the disease in cancer patients. Determining of the inflammatory response intensity in ColoRectal Cancer (CRC) patients after RadioFrequency Ablation (RFA) of liver metastatic lesions will allow to determine the group of patients who need perioperative anti-inflammatory treatment. The aim of the study was to establish predictive factors of the inflammatory response intensity in CRC patients after RFA of liver metastases. The Systemic Inflammation Response Index (SIRI) and the diameter of the largest liver metastasis were considered as predictive factors of the inflammatory response intensity. High levels of these indicators were associated with a significant increase in the inflammatory mediators’ levels after RFA. Patients with a high SIRI also showed significant immune disorders that may affect the further course of the disease. One-dimensional analysis showed that the product of SIRI and the diameter of the largest metastatic lesion (SIRI×Dmax) has the most significant accuracy in predicting of the inflammatory response intensity. The threshold value of SIRI×Dmax for predicting a high-intensity inflammatory response was determined to be 25.5. The use of the predictor of the intensity of the inflammatory response proposed by us will make it possible to separate the group of patients who, after interventional treatment of CR metastases to the liver, will need closer surveillance with a reduction in the time intervals between follow-up examinations for timely detection of recurrence. Identification of patients who are expected to have a high inflammatory response intensity will allow timely prescription of anti-inflammatory therapy and limit the negative impact of surgery on the further course of cancer.
Keywords: cancer patients, surgical treatment of metastases, systemic inflammatory response index.
References
Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. DOI: 10.1016/j.tranon.2021.101174. PMID: 3424301.
Fedorenko Z, Sumkina O, Gorokh Ye, Ryzhov A. Cancer in Ukraine, 2022–2023. Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine. 2024;25:66p. Available at: http://www.ncru.inf.ua/publications/BULL_25/index_e.htm
Fedorenko Z, Kolesnik O, Gulak L, Ryzhov A, Sumkina O. Colorectal cancer in Ukraine: the epidemiological and organizational aspects of the problem. Practical Oncology. 2019; 2(2):2-9. DOI: 10.22141/2663-3272.2.2.2019.176026.
Filippini Velazquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, et al. Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer. ESMO Open. 2022;7(3):100470. DOI: 10.1016/j.esmoop.2022.100470. PMID: 35461024.
Tohme S, Simmons RL, Tsung A. Surgery for cancer: A trigger for metastases. Cancer Res. 2017;77(7):1548-52. DOI: 10.1158/0008-5472.CAN-16-1536. PMID: 28330928.
Valderrama-Trevino AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic metastasis from Colorectal Cancer. Euroasian J Hepatogastroenterol. 2017;7(2):166-75. DOI: 10.5005/jp-journals-10018-1241. PMID: 29201802.
Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver. 2013;7(1):1-6. DOI: 10.5009/gnl.2013.7.1.1.
Hao W, Binbin J, Wei Y, Kun Y. Can radiofrequency ablation replace liver resection for solitary colorectal liver metastasis? A systemic review and meta-analysis. Front Oncol. 2020;10:561669. DOI: 10.3389/fonc.2020.561669. PMID: 33312946.
Yusupov T, Kostylieva N. Radiofrequency ablation in treatment of hepatic metastases of colorectal cancer. The Ukrainian Journal of Clinical Surgery. 2022;89(7-8):62-5. DOI: 10.26779/2522-1396.2022.7-8.62.
Evrard S, Menetrier-Caux C, Biota C, Neaud V, Mathoulin-Pélissier S, Blay J-Y, et al. Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. Gastroenterol Clin Biol. 2007;31(2):141-5. DOI: 10.1016/s0399-8320(07)89344-4.
Kim D, Gupta B, Wong GYM. Prognostic circulating proteomic biomarkers in colorectal liver metastases. Comput Struct Biotechnol J. 2023;21:2129-36. DOI: 10.1016/j.csbj.2023.03.011. PMID: 36992914.
Li Q, Chen L, Jin H, Zhao Y, Hao Z, Ma X. Pretreatment Inflammatory Markers Predict Outcomes and Prognosis in Colorectal Cancer Patients With Synchronous Liver Metastasis. Clin Med Insights Oncol. 2022;16:11795549221084851. DOI: 10.1177/11795549221084851. PMID: 35355514.
Papakonstantinou M, Fiflis S, Christodoulidis G, Giglio MC, Louri E, Mavromatidis S, et al. Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with colorectal liver metastases: A systematic review. World J Clin Oncol. 2022;13(10):822-34. DOI: 10.5306/wjco.v13.i10.822. PMID: 36337307.
Jin Z, Wu Q, Chen S, Gao J, Li X, Zhang X, et al. The associations of two novel inflammation indexes, SII and SIRI with the risks for cardiovascular diseases and all-cause mortality: A ten-year follow-up study in 85,154 individuals. J Inflamm Res. 2021;14:131-40. DOI: 10.2147/JIR.S283835. PMID: 33500649.
Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: A systematic review and meta-analysis of 38 cohorts. Dose Response. 2021;19(4):155932582110647. DOI: 10.1177/15593258211064744. PMID: 34987341.
Wang C-Z, Yan G-X, Xin H, Liu Z-Y. Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases. World J Gastrointest Oncol. 2020;12(9):1044-55. DOI: 10.4251/wjgo.v12.i9.1044. PMID: 33005297.
Thai Doan K, Nguyen Viet L, Nguyen Tien T, Nguyen Canh B, Ngo Thi H, Nguyen Thanh N, et al. Prognostic factors of radiofrequency ablation plus systemic chemotherapy for unresectable colorectal cancer with liver metastasis. Int J Hepatol. 2020;2020:8836922. DOI: 10.1155/2020/8836922. PMID: 33381321.
Lahat E, Eshkenazy R, Zendel A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr. 2014;3(5):317-23. DOI: 10.3978/j.issn.2304-3881.2014.09.07. PMID: 25392844.
Hinz S, Tepel J, Roder C, Kalthoff H, Becker T. Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases – a pilot study. Anticancer Res. 2015;35(5):2961-7. PMID: 25964582.
Ongiem A, Siriussawakul A, Aungsumat Wangdee BNS W, Homsud S, Jaiyen T. Assessment of pain severity after radiofrequency ablation in patients with hepatocellular carcinoma. J Med Assoc Thai. 2016;99(5):572-7. PMID: 27501613.
Nakagomi R, Tateishi R, Mikami S, Wake T, Kinoshita MN, Nakatsuka T, et al. Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics. PLoS One. 2021;16(11):e0259641. DOI: 10.1371/journal.pone.0259641. PMID: 34797828.
Chen R, Hou B, Zhou Y, Zhang T, Wang Z, Chen X, et al. Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors. Front Oncol. 2023;13:1018715. DOI: 10.3389/fonc.2023.1018715. PMID: 36910605.
Brierley J, Giuliani M, O'Sullivan B, Rous B, Van Eycken E, eds. TNM Classification of Malignant Tumours, 9th edition. John Wiley & Sons, 2025. 272 p.
Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359-67. DOI: 10.1038/s41416-020-01048-4. PMID: 32929195.
Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res. 2023;11(1):28 DOI: 10.1186/s40364-023-00460-1. PMID: 36890557.
Vyas M, Requesens M, Nguyen TH, Peigney D, Azin M, Demehri S. Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol. 2023;13:1098445. DOI: 10.3389/fimmu.2022.1098445. PMID: 36733396.
Yu Y. The function of NK cells in tumor metastasis and NK cell-based immunotherapy. Cancers (Basel). 2023;15(8):2323. DOI: 10.3390/cancers15082323. PMID: 37190251.
Thoren FB, Riise RE, Ousbäck J, Della Chiesa M, Alsterholm M, Marcenaro E, et al. Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism. J Immunol. 2012;188(4):1668-74. DOI: 10.4049/jimmunol.1102002.
Jiang H, Jiang J. Balancing act: the complex role of NK cells in immune regulation. Front Immunol. 2023;14:1275028. DOI: 10.3389/fimmu.2023.1275028. PMID: 38022497.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.